First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

World J Surg Oncol. 2023 Mar 2;21(1):74. doi: 10.1186/s12957-023-02935-9.

Abstract

Background: The acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance.

Case presentation: Here, we first report a female lung adenocarcinoma patient with an acquired ALK resistance mutation (ALK 11171N) who was treated with ensartinib. Her symptoms significantly improved after only 20 days, and with a side effect of mild rash. Follow-up images observed no further brain metastases after 3 months.

Conclusions: This treatment may provide a new therapeutic strategy for ALK TKIs resistant patients, especially in position 1171 of ALK exon20.

Keywords: ALK I1171N; ALK rearranged; Ensartinib; Lung caner.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Piperazines
  • Receptor Protein-Tyrosine Kinases

Substances

  • ensartinib
  • Piperazines
  • Receptor Protein-Tyrosine Kinases